Analytical Data
-
Gene name
NANP
- Application
-
Alternative Names
C20orf147; HDHD4; Haloacid Dehalogenase-Like Hydrolase Domain Containing 4; Neu5Ac-9-Pase
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9CPT3
-
Expression Region
Met1~Val248
-
Molecular Weight
33kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
NANP (Nano-attached Nanoparticle) recombinant protein research is positioned at the intersection of nanotechnology and biotechnology, aiming to enhance the effectiveness of various applications, particularly in drug delivery and vaccine development. The unique properties of nanoparticles, such as their high surface area-to-volume ratio and ability to be functionalized with biomolecules, make them ideal carriers for therapeutic agents. In the context of infectious diseases, particularly malaria, the NANP peptide, derived from the circumsporozoite protein of the malaria-causing Plasmodium species, has garnered significant attention as a target for vaccine development. By conjugating this peptide to nanoparticles, researchers aim to create robust immunogenic responses that can lead to the production of neutralizing antibodies. Furthermore, the incorporation of NANP into recombinant proteins can improve stability and efficacy, facilitating the development of novel vaccine candidates that are both effective and safe. Recent advancements in genetic engineering techniques have enabled more efficient production of these recombinant proteins, paving the way for innovative therapeutic strategies. As such, the investigation into NANP recombinant proteins is critical not only for understanding malaria pathogenesis but also for the broader application in the realm of nanomedicine, offering potential solutions to combat various infectious diseases and improve healthcare outcomes worldwide.
